VEGF Signaling: Potential Drug Targets and Biomarkers (P6910)

Target Name: Vascular endothelial growth factors (VEGF)

NCBI ID: P6910

Vascular endothelial growth factors (VEGF)

Other Name(s): VEGF

VEGF Signaling: Potential Drug Targets and Biomarkers

Vascular endothelial growth factors (VEGF) are a family of cytokines that play a crucial role in the regulation of vascular growth and maintenance. TheVEGF family consists of four isoforms: VEGF-A, VEGF-B, VEGF-C, and VEGF-D. VEGF-A is the most abundant isoform and is involved in the formation of new blood vessels, while VEGF-B and VEGF-C are involved in the regulation of angiogenesis andVEGF-D is a potent inhibitor ofVEGF signaling.

VEGF signaling is involved in the regulation of various cellular processes including angiogenesis, vascular remodeling, and tissue repair. It is well established thatVEGF signaling is a critical factor in the development and maintenance of cancer, including angiogenesis, tumor growth, and metastasis.

VEGF has been identified as a potential drug target and a biomarker for various diseases, including cancer, cardiovascular disease, and neurodegenerative diseases. Many studies have shown that inhibition ofVEGF signaling has therapeutic benefits in these diseases, including improved treatment outcomes and reduced morbidity.

One of the main mechanisms by whichVEGF signaling is involved in cancer progression is its role in the regulation of angiogenesis. New blood vessels form during the initial stages of cancer development and these vessels provide a pathway for tumor growth and metastasis. VEGF signaling is critical in the formation of these new blood vessels, and inhibition ofVEGF signaling has been shown to be effective in reducing the formation of new blood vessels and tumor growth.

VEGF is also involved in the regulation of vascular remodeling, which is the process by which the blood vessels adapt to changing blood flow demands. VEGF signaling is involved in the regulation of angiogenesis, endothelial cell proliferation, and migration, as well as the regulation of matrix metalloprotegerin (MMP) expression, which is a protein that plays a role in the regulation of vascular smooth muscle cell proliferation and contraction.

VEGF has also been shown to be involved in the regulation of tissue repair and regeneration. After injury or disease, the body's natural response is to repair damaged tissue and promote regeneration. VEGF signaling is involved in this process, as it regulates the formation of new blood vessels that supply the site of injury or disease with oxygen and nutrients, as well as the production of new cells that replace damaged or destroyed cells.

In addition to its role in cancer and tissue repair, VEGF is also involved in the regulation of normal angiogenesis, which is the process by which the body forms new blood vessels to meet the needs of the growing fetus or adult. VEGF signaling is involved in the formation of new blood vessels in the placenta and fetal brain, and it has been shown to be critical in the normal development and function of the circulatory system.

VEGF signaling is also involved in the regulation of vascular aging, which is the process by which the blood vessels age and dysfunction over time. VEGF signaling is involved in the regulation of angiogenesis, endothelial cell proliferation, and migration, as well as the regulation of matrix metalloprotegerin (MMP) expression, which is a protein that plays a role in the regulation of vascular smooth muscle cell proliferation and contraction.

VEGF has also been shown to be involved in the regulation of inflammation and immune responses. VEGF signaling is involved in the regulation of the production and function of immune cells, including T cells and natural killer cells, as well as the regulation of the production of pro-inflammatory cytokines.

In conclusion, VEGF is a critical factor in the regulation of various cellular processes that are involved in cancer, cardiovascular disease, and neurodegenerative diseases. The inhibition ofVEGF signaling has been shown to be effective in

Protein Name: Vascular Endothelial Growth Factors (VEGF) (nonspecified Subtype)

The "Vascular endothelial growth factors (VEGF) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Vascular endothelial growth factors (VEGF) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets